Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 16, 2026, discloses the granting of conditional share awards under the GlaxoSmithKline 2017 Performance Share Plan. The awards were granted on February 12, 2026, to Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs). The performance period for these awards spans three financial years, from January 1, 2026, to December 31, 2028.
Key Financial Metrics and Transaction Details
The filing does not report consolidated revenue, profit, cash flow, or debt metrics. Instead, it details specific equity compensation transactions:
- Instrument Type: Conditional awards of Ordinary Shares (GBP) and American Depositary Shares (ADS) (USD).
- Valuation: Ordinary Shares were valued at £21.50 (with one exception at £21.41); ADS were valued at $58.49.
- Total Volume: Awards were granted to 15 individuals, including the CEO, CFO, and various Presidents and Officers.
- Notable Awards:
- Luke Miels (CEO): 463,662 Ordinary Shares.
- Julie Brown (CFO): 196,548 Ordinary Shares.
- Tony Wood (Chief Scientific Officer): 247,138 Ordinary Shares.
- Maya Martinez-Davis (President, US): 53,433 ADS.
Material Changes and Performance Measures
The filing outlines the specific performance metrics determining the vesting of the 2026 awards. Vesting is contingent on achieving targets across five measures:
- Total Sales Growth (17.5%): Targets set based on Board planning and analyst consensus.
- Core Operating Profit Growth (17.5%): Targets set to incentivize over-performance.
- Pipeline Sustainability (17.5%): Based on New Molecular Entities (NMEs) or new indications adding £0.5 billion to Peak Year Sales. Vesting is conditional on the 2031 Sales outlook remaining at least £40 billion.
- Responsible Business: Composite Scorecard (7.5%): Aggregated annual performance across Responsible Business metrics.
- Relative Total Shareholder Return (TSR) (40%): Performance against a size-adjusted global biopharma peer group of 13 companies.
Vesting schedules range from nil (below threshold) to 100% (maximum target), with specific thresholds for the CEO versus other executives.
Guidance, Outlook, and Risks
Outlook Reference: The filing references GSK's 2026 guidance and 2031 Sales outlook, noting that the Pipeline Sustainability measure requires the 2031 outlook to remain at least £40 billion for any vesting to occur. Specific numerical guidance for 2026 is not detailed in this text but is referenced as being available in the Full-year and fourth quarter 2025 results announcement.
Risks and Contingencies:
- Forward-Looking Statements: The filing includes a cautionary statement that actual results may differ materially from projections due to risks described in the 2024 Form 20-F and Q4 2025 results.
- Clawback/Forfeiture: Awards lapse if performance targets are not met. Executive Directors are subject to a two-year holding period post-vesting; shares may be forfeited if terminated for cause.
- Commercial Sensitivity: Specific pipeline sales contributions and assessment matrices are not disclosed as they are commercially sensitive.
Investor Verification Checklist
- Verify the specific 2026 Total Sales and Core Operating Profit growth targets referenced in the Board's annual planning process.
- Confirm the current status of the 2031 Sales outlook to ensure it meets the £40 billion threshold required for Pipeline Sustainability vesting.
- Review the Q4 2025 results announcement for the detailed 2026 guidance and risk factors mentioned in the cautionary statement.
- Monitor the composition and performance of the 13-company peer group used for the Relative TSR calculation.
- Check for any updates to the Responsible Business Performance Rating metrics that could impact the 7.5% composite scorecard vesting.